The German-based expert for industrial biotechnology applications c-LEcta, in cooperation with a leading ingredient supplier, developed a process based on enzymatic treatment of precursors of these sweeteners. This new enzymatic treatment now makes it possible to efficiently convert the precursors into a better tasting sweetener.
These sweeteners are safe and suitable for diabetics. The cultivation is more sustainable due to the smaller use of resources required in the process.
The highly effective enzyme process helps to provide the food and beverage industry with greater supply of great-tasting, plant-based sweeteners. That increased supply helps to enable production of zero-calorie soft drinks sweetened 100 percent with plant-based sweeteners. The enzyme technology made in Germany has been incorporated at commercial scale and has the potential to enable our partner to decisively change the world market for natural sweeteners. The sweetener produced via this process is USA FDA “GRAS” which means it is available for use by food and beverage companies in the USA.
“We are very proud of what we have achieved in the framework of this close cooperation. We have already expanded our enzyme production capacities and are confident that together with our partner we will be able to provide the required quantities for large-scale use of the sweetener in the food and beverage industry”, Dr. Marc Struhalla, c-LEcta’s CEO, emphasizes. “The commercialization harbors the potential to prospectively take our sales to a new level and expands our existing product portfolio”.